This study evaluated the antiangiogenic and antioxidant properties of Calamansi Citrus microcarpa distilled essential oil and amber crude oil. Fourier Transform Infrared Spectroscopy (FTIR) and Gas Chromatography – Mass Spectrophotometry (GC-MS) analysis on the distilled essential oil revealed alkenes, alcohols, alkanes, alkyls, ketones, aldehydes, carboxylic acids and aromatics with 29 constituents, while alkenes, alkanes and hydrocarbons with 38 constituents were found in the amber crude oil. Terpenes made up most of the constituents with the monoterpenic limonene comprising majority of both oils (80.39% and 71.85%). Limonene oxide, beta-myrcene, cis-carveol and transcarveol dominated both the calamansi oils. Both register under category 5 acute oral toxicities, based on the OECD 423 Guidelines, with a toxicity range of 2000-5000 mg/kg. By CAM Assay, the antiangiogenic property was determined. There is no significant difference in the primary and secondary blood vessels but there is a significant difference in the tertiary blood vessels between the two calamansi oils and bevacizumab. Determining antioxidant activity by DPPH Assay also reveals a significant difference in the mean free radical scavenging activity between the two calamansi oils and ascorbic acid.